Ludwig In the News

June 13, 2023
The ASCO Post

This article covers a Nature study co-led by Ludwig Harvard’s Andrew Lane and Peter van Galen on how the journey of precancerous cells from the bone marrow to the skin can trigger genetic transformations that initiate a rare type of leukemia.

June 3, 2023
The ASCO Post

This profile of George Demetri covers the Ludwig Harvard co-director’s life, education, hobbies and fascinations, along with his outsize contributions to cancer research and care.

May 16, 2023

This article highlights the pioneering work done by Ludwig Harvard’s Rakesh Jain on the normalization of tumor blood vessels induced by angiogenesis inhibitors.

April 27, 2023
MedCity News

Quest Diagnostics is acquiring Haystack Oncology, which was founded by Ludwig Johns Hopkins’ Bert Vogelstein, Ken Kinzler and Nick Papadopoulos. The development of its technology was supported in good measure by a program for cancer prevention launched by Ludwig Cancer Research and the Conrad N. Hilton Foundation.

Additional coverage: The Business Journals* | GenomeWeb | MedTech Dive | STAT*| MedTech Insight | FierceBiotech | NJ Biz

April 20, 2023

This article shares new discoveries and presentations at the AACR 2023 Annual Meeting, including a presentation by Ludwig Stanford’s Siddhartha Jaiswal on CHIP, a disorder driven by the accumulation of somatic mutations in stem cells that can give rise to blood cancers and is associated with a number of other diseases.

April 13, 2023

In this article, Cell asked researchers, including Ludwig Lausanne’s Johanna Joyce and Ludwig Institute Scientific Advisor Juanita Merchant, about the questions they believe to be most important to the advancement of cancer research and care.

April 5, 2023
The Korea Herald

Ludwig Harvard’s Marcia Haigis was among the winners of the Samsung Ho-Am Prize award for this year in the fields of science, engineering, medicine, arts and community service.

March 30, 2023
News Medical

This study, led by Ludwig Lausanne Member Mikaël Pittet and Allon Klein of Harvard Medical School, identifies a functional state assumed by neutrophils following immunotherapy—termed the Sellhi state—in which they become formidable agents of antitumor immunity in mouse models of lung and colon cancer.


You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?